FINWIRES · TerminalLIVE
FINWIRES

$CGON

9 stories mentioning CGONUpdated 1d ago

Every FINWIRES story that references CGON, newest first.

Commodities

Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Tuesday Amid Renewed Pressure on Semiconductor Stocks

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.02%, and the actively traded Invesco QQQ Trust (QQQ) retreated 0.8% in Tuesday's premarket activity, as markets traded mixed amid renewed pressure on semiconductor stocks.US stock futures were also mixed, with S&P 500 Index futures up 0.1%, Dow Jones Industrial Average futures slipping 0.3%, and Nasdaq futures gaining 0.8% before the start of regular trading.The US advance international trade in goods deficit narrowed to $101.46 billion in June from $105.89 billion in May, according to data released by the US Census Bureau, compared with a narrower gap of $100 billion expected in a survey compiled by Bloomberg as of 7:40 am ET.May's home price data will be released at 9:00 am ET, followed by consumer confidence and the Richmond Federal Reserve's conditions readings, both for July, at 10:00 am ET.The Dallas Fed's nonmanufacturing index for July is due to be released at 10:30 am ET.In premarket action, bitcoin was down by 2.3%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 2.2% lower, Ether ETF (EETH) fell 3.8%, and Bitcoin & Ether Market Cap Weight ETF (BETH) was up 1.9%.Power Play:ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was up 1.7%, the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was flat, and the iShares US Consumer Staples ETF (IYK) was 0.5% higher. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) gained 0.1%. The VanEck Retail ETF (RTH) and the State Street SPDR S&P Retail ETF (XRT) were inactive.Unilever (UL) shares were up more than 8% pre-bell after the company reported higher Q2 turnover and underlying sales.Winners and Losers:FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.5%. Direxion Daily Financial Bull 3X Shares (FAS) was up 1.4%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 1.5% lower.Barclays (BCS) shares traded down 6.4% in early-hours activity even after the company reported higher Q2 earnings and total income.EnergyThe iShares US Energy ETF (IYE) was down 1.1%, while the State Street Energy Select Sector SPDR ETF (XLE) was up by 0.1%.Expro (XPRO) stock was up more than 5% before market open after the company raised its 2026 revenue guidance.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) retreated 0.1%, while the Vanguard Industrials Index Fund (VIS) was 0.7% higher and the iShares US Industrials ETF (IYJ) was flat.GE Vernova (GEV) stock was down more than 4% before the opening bell following a 1.8% loss in the prior session. The company said it was selected to replace two pumped storage units at First Hydro's Dinorwig hydropower plant in the UK.Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 1.3%, the Vanguard Health Care Index Fund (VHT) was up 0.9%, while the iShares US Healthcare ETF (IYH) gained 0.4%. The iShares Biotechnology ETF (IBB) was flat.CG Oncology (CGON) stock was up more than 1% premarket after the company reported durable responses and bladder preservation in patients with high-risk Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer in its phase 3 study of cretostimogene grenadenorepvec.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) retreated 2%, the iShares US Technology ETF (IYW) was 0.8% lower, and the iShares Expanded Tech Sector ETF (IGM) was down 1.7%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) fell 2.5%, while the iShares Semiconductor ETF (SOXX) declined by 4.2%.Nvidia (NVDA) shares were down 0.8% in premarket activity after falling 5% at the previous close, while Apple (AAPL) gained 0.4% after a 1.2% rise at Monday's close. Apple surpassed Nvidia as the world's most valuable company on Monday, marking the first time it has closed above the chipmaker since April 2025. Bloomberg reported Tuesday that Taiwanese prosecutors have detained an Nvidia employee as part of an investigation into the alleged smuggling of advanced AI chips to China.CommoditiesFront-month US West Texas Intermediate crude oil declined by 1% to $81.79 per barrel on the New York Mercantile Exchange. Natural gas was down by 1.6% to $2.72 per 1 million British Thermal Units. The United States Oil Fund (USO) was down 0.2%, while the United States Natural Gas Fund (UNG) was 1.5% lower.Gold futures for November retreated 1.2% to $4,088.50 an ounce on the Comex. Silver futures were down 2% to $57.53 an ounce. SPDR Gold Shares (GLD) decreased 1.4%, and the iShares Silver Trust (SLV) was 2.1% lower.

Dow JonesNasdaq CompositeS&P 500$AAPL$BCS$BETH$BITO$CGON$EEM$EETH$EXI$FAS$FAZ$GEV$GLD$IBB$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$NVDA$PMR$QQQ$RTH$SLV$SOXX$SPY$UL$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XPRO$XRT$XSD
Insider Trading

CG Oncology Insider Bought Shares Worth $24,814,454, According to a Recent SEC Filing

Brian Guan-Chyun Liu, Director, on June 25, 2026, executed a purchase for 371,085 shares in CG Oncology (CGON) for $24,814,454. Following the Form 4 filing with the SEC, Liu has control over a total of 1,886,236 common shares of the company, with 1,886,236 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1991792/000114036126026779/xslF345X05/form4.xml

$CGON
Sectors

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index shedding 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.7%.The iShares Biotechnology ETF (IBB) rose 0.5%.In corporate news, Cigna (CI) shares fell 1.6% after Barclays downgraded the stock to equalweight from overweight, and lowered its price target to $304 from $310.Brazil on Tuesday cleared pharmaceutical company EMS to sell the country's first generic version of Novo Nordisk's (NVO) Ozempic shot, Bloomberg reported. EMS plans to sell the generic version, called Ozivy, for 30% less than Ozempic, and it expects it to hit the market within 30 days, the report said. Novo shares were down 1.5%.Eli Lilly (LLY) said it has struck deals to buy three vaccine developers in all-cash deals with a combined value of up to $3.83 billion to build its infectious disease portfolio. Lilly shares rose 0.5%.CG Oncology (CGON) shares fell 3.8% after the firm said that Ambaw Bellete, its president and chief operating officer, will exit the company, effective June 30.

$CGON$CI$LLY$NVO
Sectors

Sector Update: Healthcare Stocks Decline Tuesday Afternoon

Healthcare stocks were lower Tuesday afternoon, with the NYSE Healthcare Index shedding 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.5%.The iShares Biotechnology ETF (IBB) rose 0.5%.In corporate news, Brazil on Tuesday cleared pharmaceutical company EMS to sell the country's first generic version of Novo Nordisk's (NVO) Ozempic shot, Bloomberg reported. EMS plans to sell the generic version, called Ozivy, for 30% less than Ozempic, and it expects it to hit the market within 30 days, the report said. Novo shares were down 1.4%.Eli Lilly (LLY) said it has struck deals to buy three vaccine developers in all-cash deals with a combined value of up to $3.83 billion to build its infectious disease portfolio. Shares rose 1.3%.CG Oncology (CGON) shares declined 2.9% after the firm said that Ambaw Bellete, its president and chief operating officer, will exit the company, effective June 30.BioRestorative Therapies (BRTX) shares jumped 18% after the firm said it has completed dosing in its phase 2 trial assessing BRTX-100 to treat chronic lumbar disc disease.

$BRTX$CGON$LLY$NVO
Wire

CG Oncology Chief Operating Officer Ambaw Bellete to Depart

CG Oncology (CGON) said in a Tuesday regulatory filing that its president and chief operating officer Ambaw Bellete will exit the company, effective June 30.The company also appointed Arthur Kuan as president, according to the filing.Price: $61.07, Change: $-3.19, Percent Change: -4.96%

$CGON
Wire

CG Oncology's Creto Combination Could Drive Better Efficacy in BCG-Exposed NMIBC, UBS Says

CG Oncology's (CGON) initial data from its phase 2 study support a potential cretostimogene and Gemcitabine combination strategy to drive better efficacy in Bacillus Calmette-Guerin-exposed non-muscle invasive bladder cancer, UBS said in a Monday note.The firm said that the cretostimogene and Gemcitabine combination showed a clean safety profile with no high-grade treatment-related adverse events, further supporting their combinability.UBS noted, however, that long-term durability of the combination remains to be seen.The firm said that the Bacillus Calmette-Guerin-exposed population is an underappreciated opportunity, and continued de-risking efficacy data could drive long-term upside.UBS has a buy rating on the stock and a $90 price target.Price: $65.36, Change: $-1.58, Percent Change: -2.35%

$CGON
Wire

CG Oncology's BLA Completion Target for Creto in Q4 to Comfort Investors, RBC Says

CG Oncology's (CGON) target to complete a biologics license application for cretostimogene monotherapy, or creto, in Q4 will provide investors with comfort, RBC Capital Markets said in a Friday note.Cretostimogene monotherapy is currently being evaluated as a treatment for high-risk non-muscle invasive bladder cancer, according to the note.The firm said that while the application completion target is later than hoped, the added clarity puts an end date on the submission, assuaging manufacturing concerns.RBC said that considering favorable regulatory designations, the therapy could receive approval toward H2 of 2027.RBC said that a readout for the PIVOT-006 trial is on track for H1 of 2026, with the drug expected to meet its endpoints and drive an about 15% jump in stock movement as a base case.The firm has an outperform speculative risk rating on the stock and increased its price target to $81 from $79.Price: $69.82, Change: $+0.20, Percent Change: +0.29%

$CGON
Wire

CG Oncology Pivot-006 Data in Early June Seen as 'Complex' Catalyst, RBC Says

CG Oncology's (CGON) Pivot-006 study, currently evaluating Cretostimogene Grenadenorepvec in intermediate-risk non-muscle invasive bladder cancer, is a "complex" catalyst, RBC Capital Markets said in a Monday note.The firm said complexity stems from limited historical data to anchor readout expectations, combined with a recent run-up in shares and a more challenging tactical setup ahead of the catalyst.RBC expects data from the trial in early June and models Cretostimogene delivering a nearly 40% risk reduction, which it estimates would drive about 20% upside in the stock. The firm also highlights a greater than $1.2 billion US opportunity in intermediate-risk disease, adding to the drug's established profile in high-risk non-muscle invasive bladder cancer.Other key catalysts include additional clinical readouts across its bladder cancer program and a potential BLA filing in H2, RBC said.The firm has an outperform, speculative risk rating on the stock and raised its price target to $79 from $73.Price: $68.66, Change: $-0.02, Percent Change: -0.03%

$CGON
Insider Trading

CG Oncology Insider Sold Shares Worth $1,138,956, According to a Recent SEC Filing

James Mulay, Director, on April 17, 2026, sold 15,600 shares in CG Oncology (CGON) for $1,138,956.SEC Filing:https://www.sec.gov/Archives/edgar/data/1991792/000119312526164013/xslF345X05/ownership.xml

$CGON

Track with the FINWIRES app suite